Axovant Sciences Ltd (NASDAQ:AXON) was the target of a significant growth in short interest in January. As of January 31st, there was short interest totalling 4,188,830 shares, a growth of 39.1% from the January 15th total of 3,010,613 shares. Based on an average daily volume of 1,081,989 shares, the short-interest ratio is currently 3.9 days. Approximately 8.0% of the company’s stock are sold short.
A number of equities analysts have weighed in on the stock. BidaskClub downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a research note on Thursday, November 8th. Zacks Investment Research raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Monday, January 7th. JMP Securities reaffirmed a “buy” rating and set a $6.00 target price on shares of Axovant Sciences in a research note on Monday. Jefferies Financial Group raised shares of Axovant Sciences from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Monday, December 17th. Finally, Oppenheimer reaffirmed a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 11th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $4.25.
NASDAQ:AXON opened at $1.22 on Thursday. Axovant Sciences has a 52 week low of $0.93 and a 52 week high of $6.59. The company has a debt-to-equity ratio of 1.24, a quick ratio of 2.02 and a current ratio of 2.02. The company has a market cap of $157.74 million, a PE ratio of -0.59 and a beta of 1.21.
Axovant Sciences (NASDAQ:AXON) last posted its quarterly earnings results on Thursday, February 7th. The biotechnology company reported ($0.27) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.27). As a group, equities analysts predict that Axovant Sciences will post -1.25 earnings per share for the current fiscal year.
In other Axovant Sciences news, major shareholder Svf Investments (Uk) Ltd bought 10,000,000 shares of the firm’s stock in a transaction on Tuesday, December 18th. The stock was acquired at an average price of $1.00 per share, with a total value of $10,000,000.00. Following the completion of the purchase, the insider now owns 99,285,714 shares of the company’s stock, valued at $99,285,714. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. 6.00% of the stock is currently owned by company insiders.
Large investors have recently bought and sold shares of the company. Geode Capital Management LLC grew its holdings in shares of Axovant Sciences by 118.1% during the fourth quarter. Geode Capital Management LLC now owns 95,087 shares of the biotechnology company’s stock valued at $94,000 after buying an additional 51,499 shares during the last quarter. GSA Capital Partners LLP grew its holdings in shares of Axovant Sciences by 22.9% during the fourth quarter. GSA Capital Partners LLP now owns 156,795 shares of the biotechnology company’s stock valued at $156,000 after buying an additional 29,200 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Axovant Sciences by 12.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 559,602 shares of the biotechnology company’s stock valued at $1,354,000 after buying an additional 64,152 shares during the last quarter. Monashee Investment Management LLC purchased a new stake in shares of Axovant Sciences during the fourth quarter valued at approximately $996,000. Finally, Hudson Bay Capital Management LP grew its holdings in shares of Axovant Sciences by 23.8% during the fourth quarter. Hudson Bay Capital Management LP now owns 1,250,000 shares of the biotechnology company’s stock valued at $1,245,000 after buying an additional 240,000 shares during the last quarter. Hedge funds and other institutional investors own 7.58% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Macon Daily and is the property of of Macon Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international copyright and trademark laws. The correct version of this piece of content can be read at https://macondaily.com/2019/02/14/axovant-sciences-ltd-axon-short-interest-up-39-1-in-january.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in acquisition, development, and commercialization of therapeutics in the fields of neurology and psychiatry in the United States and the European Union. It focuses on developing AXO-Lenti-PD, an in vivo lentiviral gene therapy investigational product candidate for the one-time treatment of Parkinson's disease.
Featured Article: What are retained earnings?
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.